GlassScriptPhysician profile
Michelle R Basye
NPI 1366143968
$2,846.20
in general payments reported to CMS, 2019-2025
41 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $718 · 2024: $437 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,736 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.39 |
| Education | $109.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $412.17 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $291.67 | 2023-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $242.34 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $196.28 | 2023-2025 | Imfinzi, Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $180.64 | 2023-2025 | |
| Lilly USA, LLC | $147.56 | 2023-2025 | |
| Abbvie INC. | $134.02 | 2024-2025 | |
| Astellas Pharma US INC | $133.32 | 2024-2025 | Cresemba, Padcev, Vyloy |
| Regeneron Healthcare Solutions, INC. | $116.91 | 2023-2025 | Libtayo |
| Pharmacosmos Therapeutics INC. | $86.68 | 2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $72.44 | 2024-2025 | Fruzaqla, Iclusig |
| Pfizer INC. | $71.92 | 2023-2025 | |
| Incyte Corporation | $70.70 | 2023-2025 | Jakafi, Monjuvi |
| Genentech USA, INC. | $68.18 | 2025 | Tecentriq Hybreza, Venclexta, Itovebi |
| Taiho Oncology, INC. | $66.94 | 2024-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $46.09 | 2025 | Zejula, Jemperli |
| Genzyme Corporation | $40.42 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $31.45 | 2023-2025 | Fotivda |
| Revance Therapeutics, INC. | $29.35 | 2025 | Daxxify |
| Emd Serono, INC. | $28.05 | 2025 | |
| Seagen INC. | $26.43 | 2023 | Padcev |
| Sumitomo Pharma America, INC. | $20.80 | 2025 | Orgovyx |
| Accord Healthcare, INC. | $20.76 | 2025 | |
| Agios Pharmaceuticals, INC. | $20.48 | 2025 | Pyrukynd |
| Genmab U.S., INC. | $19.38 | 2025 | Epkinly |
| Azurity Pharmaceuticals, INC. | $19.29 | 2024 | Vivimusta |
| Tersera Therapeutics LLC | $18.32 | 2024 | Zoladex |
| Rigel Pharmaceuticals, INC. | $18.11 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Pharmaand Gmbh | $18.10 | 2025 | Rubraca |
| Tolmar, INC. | $18.10 | 2025 | Rubraca, Eligard |
| Melinta Therapeutics, LLC | $17.83 | 2024 | Rezzayo, Orbactiv |
| Jazz Pharmaceuticals INC. | $17.72 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.22 | 2023 | Gilotrif |
| Puma Biotechnology, INC. | $16.78 | 2024 | |
| Geron Corporation | $16.64 | 2025 | Rytelo |
| Blueprint Medicines Corporation | $16.53 | 2025 | Ayvakit |
| Caris Mpi, INC. | $16.34 | 2025 | Mi Cancer Seek |
| Coherus Oncology, INC. | $15.66 | 2025 | Loqtorzi |
| Beone Medicines USA, INC. | $15.54 | 2025 | Tevimbra |
| Novocure INC. | $15.40 | 2024 | Optune Lua (Novottf-200t) |
| Beigene USA, INC. | $13.64 | 2024 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Basye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.